Synlogic

About

Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases.

Cambridge,Massachusetts,United States
51 - 100
http://synlogictx.com/

Highlights

Details

Last Funding Type: Post-IPO Equity
Last Funding Money Raised: $50.01M
Industries: Biotechnology,Health Care,Therapeutics
Founded date: Jan 1, 2014
Number Of Employee: 51 - 100
Operating Status: Active
Stock Symbol: nasdaq:SYBX
Legal Name: Synlogic, Inc.

Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases. The company's lead programs target patients with rare genetic metabolic diseases, including phenylketonuria and secondary hyperoxaluria. Synlogic is also hard at work on synthetic biotics to address more prevalent conditions, including inflammatory bowel disease, cancer, and other metabolic conditions.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

9

$321.41M

Synlogic has raised a total of $321.41M in funding over 2 rounds. Their latest funding was raised on Sep 22, 2021 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Sep 22, 2021	Post-IPO Equity	$45M	—	—	—	Detail
Apr 16, 2021	Post-IPO Equity	$30M	—	—	—	Detail
Jun 12, 2019	Post-IPO Equity	$80M	1	Ginkgo Bioworks	—	Detail
Jan 23, 2018	Post-IPO Equity	$50.01M	—	—	—	Detail
Aug 28, 2017	IPO	—	—	—	—	Detail

Investments

Number of Investments

Number of Lead Investments

1

0

Synlogic has made 1 investments. Their most recent investment was on Dec 1, 2022, when Secjur raised €5.50M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Dec 1, 2022 Secjur	Seed	€5.50M	Artificial Intelligence	—

Investors

Number of Lead Investors

Number of Investors

5

13

Synlogic is funded by 13 investors. Ginkgo Bioworks and Bill & Melinda Gates Foundation are the most recent investors.

Investor Name	Lead Investor	Funding Round
Ginkgo Bioworks	Yes	Post-IPO Equity
Bill & Melinda Gates Foundation	Yes	Series A
Aju IB Investment	—	Series C
Ally Bridge Group	—	Series C
Arctic Aurora LifeScience	—	Series C
Atlas Venture	—	Series C
CLI Ventures	—	Series C
Daphne Teo	—	Series C
Deepfield	—	Series C
New Enterprise Associates	—	Series C